HALO earnings analysis
What we found in HALO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Halozyme Therapeutics, Inc. reported strong Q1 2026 results, achieving revenue of $376.7 million and diluted EPS of $1.22, exceeding consensus estimates of $358.8 million and $1.51, respectively. The company maintained its full-year revenue guidance between $1.71 billion and $1.81 billion, indicating continued growth momentum.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 42% YOY
- Halozyme's revenue reached $376.7 million, a 42% increase compared to $265 million in Q1 2025.
- Above Consensus EPS Estimates
- The reported diluted EPS of $1.22 surpassed the estimated $1.51 for the quarter.
- Strong Royalty Revenue Increase
- Total royalties increased to $240.7 million, up 43% from the prior year, driven by strong sales of partner products.
- Increased Cash Position
- Cash and cash equivalents rose to $318.6 million as of March 31, 2026.
- Operating Cash Flow Increase
- Net cash provided by operating activities was $180.1 million, up from $154.2 million in Q1 2025.
- New Share Repurchase Program
- A new share repurchase program was authorized to buy back up to $1 billion by December 31, 2028.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Litigation Costs
- Increased legal expenditures due to ongoing patent infringement litigation.
- Decline in Other Royalty Products
- Price erosion expected on older ENHANZE partner products like Herceptin and MabThera.
- Dependence on Pipeline Success
- Revenue growth is heavily reliant on the success of upcoming product launches and collaborations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.22
What they said about what is next.
Full year revenue guidance reiterated: $1.71B-$1.81B with growth anticipated.
The filing reads better than the one before it.
What came before.
- 10-K · February 17, 2026
- Halozyme positions itself as a leader in subcutaneous (SC) drug delivery via its ENHANZE technology (rHuPH20) and has expanded its platform with Hypercon and Surf Bio; the company recorded strong 2025 revenue driven by…
- 10-Q · August 6, 2024
- Halozyme reported Q2 total revenues of $231.353M (up $10.315M, +4.7% vs Q2 2023 $221.038M) with diluted EPS of $0.72 (vs $0.56 in Q2 2023). Gross margin expanded to ~82.9% and operating margin widened to ~50.7%…
- 10-Q · May 7, 2024
- Halozyme reported Q1 (period ended March 31, 2024) revenue of $195.9M, up from $162.1M a year ago, driven by higher royalties and collaborative revenue. Operating income rose to $95.5M (operating margin ~48.8%) and GAAP…
- 10-Q · August 9, 2022
- Halozyme reported Q2 revenue of $152.365M, up 11.7% year-over-year, driven by higher royalties and product sales, but GAAP diluted EPS declined to $0.16 from $0.62 a year ago. Operating income fell sharply to $34.060M…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HALO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever